Predictive Genetic Testing: Disease Risk, Results, and What It Means

Predictive genetic testing looks for inherited variants associated with a disease that a person does not currently have. It can identify an increased chance of conditions such as hereditary cancer, cardiomyopathy, or some neurologic disorders, and it may allow screening or prevention to begin earlier. In other situations, testing can reveal a near-certain future diagnosis for a condition with no proven way to prevent it. Those are very different decisions even though both are called predictive testing.

The clearest test usually starts with a known pathogenic variant in an affected relative. Testing an unaffected person first, without knowing the family’s cause, can produce a negative result that is difficult to interpret. A positive result may change medical care and can have implications for siblings, children, and extended relatives. A negative result may be reassuring only when the laboratory specifically tested for the familial variant. Genetic counseling helps define the question, prepare for possible outcomes, and connect the result to a realistic care plan.

• Predictive testing estimates future disease risk in someone without current signs of the tested condition.
• A positive result can mean increased susceptibility or, for some conditions, very high likelihood of future disease.
• A true negative is most informative when a known familial pathogenic variant is absent.
• An uninformative negative does not rule out inherited risk when no family variant has been identified.
• Testing children for adult-onset conditions is usually deferred unless results would change care during childhood.
• The best time to test is when the result can guide screening, prevention, treatment planning, or a well-considered personal decision.

Table of Contents

• Predictive Versus Presymptomatic Testing
• Who May Consider Testing
• Why Testing an Affected Relative First Helps
• Possible Results and Their Meaning
• Medical and Family Implications
• Emotional, Privacy, and Life-Planning Issues
• Testing Children and Young People
• Preparing for and Acting on a Result

Predictive Versus Presymptomatic Testing

Predictive testing is an umbrella term for testing an asymptomatic person to learn about future disease. Two concepts sit within it.

Predispositional testing identifies a variant that raises risk but does not make disease inevitable. Pathogenic variants in BRCA1, BRCA2, Lynch syndrome genes, or some cardiomyopathy genes are examples. Penetrance—the proportion of variant carriers who develop the condition—is incomplete. Risk may depend on age, sex-related biology, family history, environmental exposures, other genes, and preventive care.

Presymptomatic testing identifies a variant expected to lead to disease if the person lives long enough, although age at onset and severity may remain uncertain. Huntington disease is the classic example. Some families use “predictive testing” for both categories, so the exact penetrance and actionability matter more than the label.

Predictive testing differs from several related tests:

• A diagnostic genetic test evaluates someone who already has symptoms or a related diagnosis.
• Carrier testing looks for recessive or X-linked variants that mainly affect reproductive risk.
• Prenatal and preimplantation testing assess a pregnancy or embryo for a defined genetic condition.
• A polygenic risk score combines many common variants to estimate susceptibility to a complex disease; it usually has smaller individual effects than a pathogenic Mendelian variant.
• Pharmacogenetic testing predicts aspects of medication response rather than future disease.

The distinction can change how a result should be handled. A pathogenic APC variant associated with familial adenomatous polyposis may trigger colon surveillance beginning in childhood or adolescence. A pathogenic Huntington disease variant does not offer a comparable preventive screen, and testing follows a deliberative protocol centered on informed choice and psychological readiness.

A genetic result is not the same as a forecast date. Even highly penetrant variants may not reveal when symptoms will start, how fast they will progress, or which manifestations will occur. In lower-penetrance conditions, the result may shift risk from population level to a broad range rather than provide a precise percentage.

The test’s purpose should be stated before ordering. “I want to know my DNA” is too broad for a high-stakes medical result. A clearer question might be: “My mother has a pathogenic MYBPC3 variant; did I inherit it, and would that change heart screening?”

Who May Consider Testing

Predictive testing is most informative for a person with a documented familial pathogenic or likely pathogenic variant. It may also be considered when the family pattern strongly suggests a hereditary condition and an affected relative is unavailable, though interpretation becomes more difficult.

Situations that may justify referral include:

• multiple relatives with the same or related cancers, especially at young ages;
• ovarian, pancreatic, metastatic prostate, male breast, or certain combinations of cancer in a family;
• sudden unexplained deaths, cardiomyopathy, dangerous arrhythmias, aortic disease, or very high cholesterol at young ages;
• a known inherited neurologic condition such as Huntington disease or some hereditary ataxias;
• a relative with a pathogenic variant found through clinical testing;
• a family history of kidney, endocrine, eye, hearing, or metabolic disorders with a recognized adult-onset form;
• belonging to a population in which a specific founder variant is more common, when the personal or family context supports testing; or
• a pathogenic secondary finding reported from prior exome or genome sequencing.

Family history should include both sides of the family and at least three generations when possible. Record the diagnosis, age at diagnosis, current age or age at death, and any genetic report. “Cancer” is less useful than “colon cancer at 42.” “Heart problem” is less useful than “hypertrophic cardiomyopathy with an MYH7 pathogenic variant.” Pathology reports, death certificates, and genetic reports can correct family stories that changed over time.

Testing may not be the first step when the suspected condition has no identified familial variant. A genetics professional may recommend testing an affected relative, obtaining medical records, using a disease-specific risk model, or continuing clinical surveillance based on family history.

Population screening is expanding for selected inherited risks, but predictive testing still differs from a general health screen. In an unselected person, the chance of finding a result, the meaning of a negative result, and the likelihood of uncertain findings differ from testing someone in a high-risk family.

A person may reasonably decide not to test. The right not to know is especially important when no prevention is available and the result could affect identity, relationships, or life plans. Declining testing does not mean declining all care; family-history-based screening may still be recommended.

Testing should not be used to explain vague symptoms without a clinical evaluation. If symptoms are present, the question may have shifted from predictive to diagnostic, which can change the test design and urgency.

Why Testing an Affected Relative First Helps

Testing begins most efficiently with someone who has the family condition. This is called testing the proband or an affected relative. The goal is to identify the exact molecular cause before testing healthy relatives.

Suppose a family includes three relatives with early colon cancer. If an affected relative is found to carry a pathogenic MSH2 variant, an unaffected sibling can receive a focused test for that exact variant. A negative result then becomes a true negative: the sibling did not inherit the known familial cause and generally returns toward population-based screening, adjusted for any remaining non-genetic history.

If the unaffected sibling instead receives a broad panel first and no pathogenic variant is found, the result may be uninformative. The family could have a variant the test missed, a gene not yet known, or a non-genetic clustering of disease. The sibling’s family-history risk may remain elevated.

Testing an affected relative can also:

• identify which gene is involved when several syndromes overlap;
• distinguish an inherited germline variant from a tumor-only change;
• reduce the number of uncertain variants reported to healthy relatives;
• clarify the appropriate inheritance pattern and recurrence risk;
• allow less expensive targeted testing for relatives; and
• create a precise family letter for cascade testing.

The best affected person is often the relative with the youngest diagnosis, the rarest or most characteristic manifestation, multiple related conditions, or the closest relationship to the person seeking testing. A living relative with available medical records is usually preferable, but stored tissue or prior reports may sometimes help when no affected relative is alive.

Do not rely on a verbal statement that “the family has the gene.” Request the original report. Gene names, variant notation, classification, laboratory, and date matter. A variant that was uncertain years ago may now be benign or pathogenic. A report might also show that only tumor tissue—not blood or saliva—was tested.

Targeted familial testing is not always sufficient. If a relative’s phenotype differs substantially or another branch of the family has a separate pattern, a broader panel may be appropriate. Families can carry more than one inherited condition.

Cascade testing means systematically offering testing to biological relatives after a pathogenic variant is identified. It is more efficient than starting from scratch in each person. Because laboratories and health systems usually cannot contact relatives directly, the tested person often becomes the bridge. Genetics clinics can provide letters that explain the result without requiring the person to interpret complex details.

Possible Results and Their Meaning

Predictive test reports use standard variant categories, but the personal meaning depends on whether the family’s pathogenic variant was known before testing.

Positive: pathogenic or likely pathogenic variant detected

A positive result means the laboratory found a variant with sufficient evidence of disease association. It does not always mean the person currently has disease. The clinician should identify penetrance, age-related risk, expected manifestations, and whether the result fits the family history.

For a predisposition syndrome, risk may be expressed as a range rather than one number. Estimates can change as larger studies include more diverse families and less severely affected people. A high-risk clinic may use gene-specific, age-specific, and sex-specific data rather than an old lifetime estimate from heavily affected families.

For a presymptomatic condition, a positive result may make future disease highly likely, but timing and severity often remain uncertain. This uncertainty should be discussed before testing, not discovered in the result appointment.

True negative for a known familial variant

A true negative means the exact family variant was not detected. The person generally is not at increased genetic risk from that variant and cannot pass it to children. This can end intensive gene-specific surveillance that was based solely on carrier risk.

A true negative does not eliminate ordinary population risk or risks from other family factors. If the person has separate symptoms, another strong branch of family history, or an independent risk factor, those still require care.

Uninformative negative

An uninformative negative occurs when no pathogenic variant is found but no definitive family cause was known. It does not prove that the condition is not inherited. Management often remains based on personal and family history.

Reasons include incomplete test coverage, an unknown disease gene, a hard-to-detect variant, a non-genetic cause, or the possibility that the tested person did not inherit the family risk but the test cannot demonstrate it.

Variant of uncertain significance

A variant of uncertain significance, or VUS, lacks enough evidence to be classified as harmful or benign. It should not be used as a positive predictive result, should not direct irreversible prevention, and usually should not be used for predictive testing of healthy relatives.

Relatives may be tested in a structured segregation study when a laboratory or genetics team believes it can clarify the variant. That is different from telling every relative to get tested because a VUS “runs in the family.”

Benign or likely benign variant

Benign findings do not explain inherited disease risk. Many are normal human variation and may be omitted from the clinical report.

Unexpected or secondary finding

Broad panels, exome sequencing, or genome sequencing can identify a risk unrelated to the original question. Consent should explain which secondary findings are returned and whether the person can opt out. A secondary result still requires confirmation and condition-specific assessment.

Result	What it establishes	Usual management basis
Pathogenic familial variant present	The person inherited the known family risk	Gene-specific guidance plus personal factors
Known familial variant absent	True negative for that variant	Population care unless other risks remain
No variant found without a known family cause	Cause remains unresolved	Family history and clinical findings
VUS	Risk effect is unknown	Do not treat as positive; monitor reclassification

Medical and Family Implications

A result has clinical value only when it connects to an appropriate plan. For hereditary cancer, that may involve earlier imaging, shorter screening intervals, preventive medication, or risk-reducing surgery. For inherited heart disease, it may lead to electrocardiograms, echocardiograms, rhythm monitoring, exercise counseling, or family emergency awareness. For aortic conditions, it can guide imaging and blood-pressure management. For very high inherited cholesterol, it can support early lipid treatment.

Management must be gene specific. Two genes associated with the same organ can carry different risks and surveillance schedules. Even within one gene, variant type, age, family history, and existing findings may affect care. A generic “positive genetic test” plan is unsafe.

A positive result can also affect treatment if disease later develops. Some hereditary cancer genes influence surgery or drug selection. Certain cardiac genotypes affect exercise or device discussions. These possibilities should be presented accurately without implying that every carrier will need intervention.

Family implications follow inheritance:

• Autosomal dominant: Each child, sibling, or parent of a carrier often has a 50% chance of the familial variant, though de novo variants and mosaicism can change the family pattern.
• Autosomal recessive: An unaffected person with one variant is usually a carrier; disease risk for children depends on the reproductive partner.
• X-linked: Risks differ by the carrier’s sex-related chromosome pattern and the child’s inherited chromosome.
• Mitochondrial: Pathogenic mtDNA variants usually pass through the maternal line, with variable heteroplasmy and severity.

A 50% inheritance chance is not a 50% chance of disease when penetrance is incomplete. First determine the chance of inheriting the variant, then the chance that a carrier develops specific manifestations.

Cascade testing should usually target the known familial variant. Broad panels in every relative can generate unrelated uncertainty and unnecessary cost. The family letter should state the gene, variant, condition, inheritance, and where a relative can obtain counseling.

Reproductive options may include natural conception, prenatal diagnosis, preimplantation genetic testing, donor gametes, adoption, or choosing not to pursue testing. None is automatically preferred. The choice depends on the condition, penetrance, severity, reproductive goals, access, and values.

A person may want to tell relatives but not know how. It is reasonable to share the laboratory report or clinic letter rather than provide a personal explanation of every risk. For estranged relatives, a genetics service may discuss privacy-respecting options available under local practice and law.

Emotional, Privacy, and Life-Planning Issues

Predictive testing can bring relief, clarity, grief, guilt, anger, or mixed feelings. A negative result may relieve fear but create survivor guilt when siblings test positive. A positive result can make a healthy person feel like a patient. An uncertain result can prolong the very ambiguity testing was meant to resolve.

Emotional readiness does not mean feeling calm. It means understanding the possible results, having support, and knowing how the information will be used. Before testing, consider:

• Do I want this information now?
• What would I do with a positive, negative, or uncertain result?
• Is there medical action available?
• Who will attend the result visit or support me afterward?
• How might this affect family relationships?
• Do I have current mental health concerns that need support first?
• Would I prefer time to address insurance, employment, or financial planning questions?

For highly penetrant neurodegenerative conditions, protocols may include several counseling visits, neurologic assessment, psychological screening, a support person, and a planned disclosure appointment. The process protects voluntary choice and reduces impulsive testing. It should not be reduced to mailing a saliva kit.

Privacy protections vary by country and type of insurance. In the United States, federal genetic nondiscrimination law has important limits and generally does not cover life, disability, or long-term-care insurance. State laws differ. People should obtain current, jurisdiction-specific advice before testing rather than assume genetic information is protected in every setting.

Medical records may include the result, and relatives may infer their own risk from it. Testing should remain voluntary, with clear consent about data storage, laboratory policies, research use, and recontact. Consumer testing adds separate questions about data sharing, account security, sample retention, and whether medical confirmation is required.

A result can influence education, career, relationships, finances, and reproductive timing even when no immediate medical action exists. These are legitimate considerations, but they do not create one correct decision. Some people value certainty; others prefer not to know until care can change.

Psychological studies generally show that carefully selected and counseled adults often adapt to predictive results, but average findings do not predict one person’s response. Anyone with severe anxiety, depression, suicidal thoughts, coercion, or family conflict deserves additional support and may choose to postpone testing.

Testing Children and Young People

Predictive testing of minors is usually recommended when the result will change medical care before adulthood. Examples include conditions requiring childhood surveillance, preventive treatment, dietary management, or avoidance of a serious risk.

Testing is generally deferred for adult-onset conditions when no childhood intervention is indicated. Deferral preserves the young person’s future autonomy—the ability to decide as an informed adult whether they want to know. It also avoids labeling a healthy child years before the information can help medically.

The line is not based only on whether a condition is called “adult onset.” Some hereditary cancer or cardiac syndromes begin surveillance in adolescence. Familial adenomatous polyposis can require gastrointestinal screening during childhood. Certain cardiomyopathy or arrhythmia genes may justify early evaluation. In those cases, testing can be medically appropriate.

Factors to consider include:

• age at which disease can begin;
• age at which surveillance or prevention starts;
• reliability of the familial variant;
• the young person’s maturity and preference;
• family anxiety and possible coercion;
• psychosocial effects of carrier labeling;
• confidentiality as the child matures; and
• a plan for communicating results over time.

Children should receive age-appropriate information and participate in the decision when capable. Parental permission does not remove the need to respect the child’s assent and emerging autonomy.

Testing a child solely to reduce a parent’s uncertainty is usually not enough when there is no childhood benefit. A genetics professional can help the family create a plan for revisiting the decision later.

When a child already has suggestive symptoms, testing is no longer purely predictive. Diagnostic evaluation may be appropriate even for a condition more common in adults.

Preparing for and Acting on a Result

A well-designed predictive test process begins before sample collection.

First, define the familial finding. Obtain the original report and confirm that the variant remains pathogenic or likely pathogenic. If no family cause is known, identify the best affected relative for testing.

Second, choose a test that matches the question. Targeted testing is usually best for a known family variant. A broader genetic panel may be appropriate when the family phenotype overlaps several genes or the original testing was incomplete.

Third, discuss the possible outcomes. Include the chance of a VUS, incidental findings, test limitations, privacy, cost, and who will receive results. Decide whether the person wants secondary findings from broader sequencing.

Fourth, write the care plan in advance. For each possible result, identify which specialist, screening schedule, or prevention discussion would follow. A test without a post-result pathway can leave the person with information but no support.

After a positive result:

1. Confirm that the result fits the familial variant and was performed in an appropriate clinical laboratory.
2. Arrange condition-specific baseline evaluation.
3. Use current professional guidance rather than generic internet risk figures.
4. Discuss relatives and provide a family letter.
5. Address reproductive options when relevant.
6. Review emotional support and privacy concerns.
7. Set a date for follow-up as guidance evolves.

After a true negative, document exactly which familial variant was absent. Ask whether any screening can return to population recommendations and whether separate family-history factors remain.

After an uninformative negative, do not discard the family history. Ask whether updated testing, reanalysis, another affected relative, or periodic review is appropriate. Genetic knowledge and laboratory methods change.

After a VUS, avoid irreversible management based on the uncertain finding. Keep contact information current and ask how reclassification will be communicated.

Seek ordinary clinical evaluation for symptoms regardless of predictive status. A positive carrier result does not prove every symptom comes from the gene, and a negative result does not make new symptoms harmless.

The best predictive testing decision is not always “yes.” It is the choice made with a clear question, reliable family evidence, voluntary consent, realistic expectations, and a plan for whatever the result shows.

References

• Predictive and Presymptomatic Genetic Testing in Adults: A Position Statement of the Human Genetics Society of Australasia 2024 (Position Statement)
• Cascade counselling and testing. Recommendations of the European Society of Human Genetics 2025 (Guideline)
• Predictive Genetic Testing in the Cancer Management and Prevention Era: A Comprehensive Review 2025 (Review)
• Systematic evidence review and meta-analysis of pre- and post-test genetic counseling for hereditary cancer risk assessment 2024 (Systematic Review)
• Cancer Genetics Overview (PDQ®)–Health Professional Version 2025 (Review)
• Genetic Testing of Minors for Adult-Onset Conditions 2025 (Position Statement)

Disclaimer

This information is educational and does not replace individualized genetic counseling, medical care, or legal and insurance advice. Predictive results should be interpreted using the exact familial variant, inheritance pattern, penetrance evidence, personal history, and current clinical guidelines. Seek prompt medical evaluation for symptoms even if a prior predictive test was negative.